JPRN-UMIN000003092
Completed
未知
The exploratory study for the efficacy and the safety of rikkunshito on symptoms of upper gastrointestinal tract in the patients with gastroesophageal reflux disease (GERD) - The exploratory study for the efficacy of rikkunshito in the GERD patients
ConditionsGERD patients
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- GERD patients
- Sponsor
- Chiba University Hospital
- Enrollment
- 100
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Patients with severe cardiac failure, acute inflammatory disease or other severe complications 2\) Patients who are pregnant, considering pregnancy or lactation 3\) Patients with serious disorder in liver, gallbladder, or pancreas 4\) Patients with gastrectomy 5\) Patients who are intolerant to oral administration 6\) Patients who received drugs prohibited for concomitant use during the observation period 7\) Patients during treatment by traditional Japanese medicines 8\) Patients considered inappropriate by the study investigator
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
The exploratory study for the efficacy and the safety of Rikkunshito on symptoms of indigestion in the patients with Functional HeartburFunctional HeartburnJPRN-UMIN000029668ippon Medical School Graduate School of Medicine20
Completed
Not Applicable
The exploratory study for the efficacy and the safety of Hangeshashinto on symptoms of heartburn /belch in the patients with gastroesophageal reflux disease (GERD)GERDJPRN-UMIN000021251Osaka Medical College80
Completed
Not Applicable
The exploratory study for the efficacy and the safety of Daikenchuto(TJ-100) on abdominal pain and abdominal fullness feeling in the patients with fecal incontinence.Abdominal pain and abdominal fullness feeling in the patients with fecal incontinenceJPRN-UMIN000030252Medical Corporation Seiaikai, Gion Usshita Hospital50
Recruiting
Phase 2
Exploratory Study to Evaluate the Efficacy and Safety of Baricitinib in Interstitial Pneumonia Associated with Anti-MDA5 Antibody-Positive DermatomyositisInterstitial pneumonia associated with anti-MDA5 antibody-positive dermatomyositisJPRN-jRCTs031220641Fujio Keishi5
Active, not recruiting
Phase 1
Exploratory study to evaluate the efficacy and safety of nutritionally administering 1.5 g protein/kg/day vs. 1.0 g protein/kg/day in the catabolic phase of the critically ill patient on mechanical ventilatioAcquired Weakness in the Intensive Care Unit (DAUCI) of the critically ill patient.MedDRA version: 20.0Level: PTClassification code 10077255Term: Intensive care unit acquired weaknessSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Not possible to specifyEUCTR2021-002329-56-ESSociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC)200